Caplin gets USFDA nod for Neostigmine Methylsulfate Injection

Caplin gets USFDA nod for Neostigmine Methylsulfate Injection

57
USFDA
Picture: Pixabay

Caplin Steriles, a subsidiary company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA).


Also read more about Caplin Steriles, click here


Medicine Injection drug vaccine
Picture: Pixabay

This ANDA is for Neostigmine Methylsulfate Injection USP, 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL), Multiple-Dose vial presentations, a generic therapeutic equivalent version of (RLD), BLOXIVERZ Injection, of Exela Pharma Sciences, LLC.

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolarising neuromuscular blocking agents (NMBAs) after surgery.

According to IQVIA (IMS Health), Neostigmine Methylsulfate Injection had US sales data of approximately $20 million for the 12-month period ending Dec 2020.


Also read:

Gilead gets USFDA nod to treat metastatic urothelial cancer

NATCO gets tentative USFDA nod for Ibrutinib tablets

First AI device to help detect colon cancer gets USFDA nod

Aleor gets tentative USFDA nod for drug for topical treatment

Zydus Cadila gets final USFDA nod for drug to treat High…

Dr Reddy’s launch generic Sapropterin Dihydrochloride Powder for Oral Solution in…

Subscribe for daily free updates

Telegram
WhatsApp
Facebook
LinkedIn

Enter your email address:

Delivered by FeedBurner